Intraocular Concentrations of Cytokines and Chemokines in Rhegmatogenous Retinal Detachment and the Effect of Intravitreal Triamcinolone Acetonide

详细信息    查看全文

• 作者：Hiroshi Kunikata^a ; ^{kunikata@oph.med.tohoku.ac.jp}Author Vitae ; Masayuki Yasuda^a ; Naoko Aizawa^a ; Yuji Tanaka^a ; Toshiaki Abe^b ; Toru Nakazawa^a
• 刊名：American Journal of Ophthalmology
• 出版年：2013
• 出版时间：June, 2013
• 年：2013
• 卷：155
• 期：6
• 页码：1028-1037.e1
• 全文大小：1517 K

文摘

| Figures/TablesFigures/Tables | ReferencesReferences

Purpose

To investigate the role of intravitreal injection of triamcinolone acetonide (IVTA) in preventing photoreceptor apoptosis in eyes with rhegmatogenous retinal detachment (RRD) by measuring cytokine levels in the aqueous humor before and after IVTA.

Design

Prospective, nonrandomized, interventional case series.

Methods

setting: Institutional. patients: Nineteen eyes of 19 consecutive patients with RRD. intervention: All 19 eyes underwent IVTA 1?day before 25-gauge vitrectomy. Seventeen eyes free of retinal vascular disease served as controls. main outcome measure: Both baseline and 1?day post-IVTA measurements were made of the relative concentrations of 15 soluble factors (3 cytokines, 7 chemokines, and 5 growth factors). The associations with clinical findings, including macular status, were then analyzed.

Results

Elevated monocyte chemotactic protein 1?(MCP-1), macrophage inflammatory protein 1¦Â (MIP-1¦Â), and interferon ¦Ã-induced protein 10 (IP-10) in eyes with RRD were significantly reduced after IVTA. MCP-1 levels were significantly correlated with MIP-1¦Â and IP-10 before and after IVTA. The decreases in MCP-1, MIP-1¦Â, and IP-10 were also closely correlated to each other. Both before and after IVTA, MCP-1 was higher in eyes with macula-off RRD than in eyes with macula-on RRD.

Conclusions

IVTA suppressed elevated levels of intraocular MCP-1, MIP-1¦Â, and IP-10 in eyes with RRD. The decrease in the aqueous levels of each of these factors was significantly correlated with the others. In addition to MCP-1, MIP-1¦Â and IP-10 might potentially be additional target molecules for RRD therapy.